Category Archives: New medicines

NPC Archive Item: Dabigatran etexilate▼ has benefits over warfarin in patients with atrial fibrillation, but long-term evidence on efficacy and safety is required

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 November 2010 An editorial in the British Medical Journal discusses the role of dabigatran etexilate▼ in patients with atrial fibrillation (AF) and concludes that it has some benefits but […]

NPC Archive Item: DURATION-3; when added to metformin or metformin plus a sulphonylurea, weekly exenatide improves disease-orientated outcomes compared with insulin glargine

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 Long-acting exenatide 2mg once weekly was more effective at reducing HbA1c than insulin glargine (titrated to glucose targets), when added to metformin or metformin plus sulphonylurea, […]

NPC Archive Item: DURATION-2; weekly exenatide in type 2 diabetes has disease-orientated outcome benefits when compared with metformin plus either sitagliptin▼ or pioglitazone▼

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 Exenatide 2mg once weekly injection was more effective at reducing HbA1c than maximum oral doses of either sitagliptin▼ or pioglitazone▼, when added to metformin, in the […]

NPC Archive Item: Extended DURATION-1 trial of exenatide weekly in type 2 diabetes demonstrates sustained reduction in HbA1c; no patient-orientated outcomes reported

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 We have previously discussed the 30-week DURATION-1 trial of long-acting exenatide 2mg once weekly versus 10micrograms exenatide▼ twice daily in adults with type 2 diabetes (T2DM). In […]

NPC Archive Item: Key licensing studies for indacaterol in COPD published

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 31 August 2010 Indacaterol▼ inhaled once daily improved trough FEV1 at 12 weeks compared to placebo in patients with moderate to severe COPD. Results from the 52-week INVOLVE study […]

NPC Archive Item: Pre-planned analysis of PLATO study of aspirin plus ticagrelor or clopidogrel in patients undergoing early invasive intervention for ACS

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 August 2010 Early invasive intervention for acute coronary syndrome was planned for 13,408 patients in this pre-specified analysis of the PLATO study (total n=18,624). After 12 months, ticagrelor plus […]

NPC Archive Item: Lasofoxifene for postmenopausal osteoporosis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15 April 2010 In the PEARL study of 8,556 women with postmenopausal osteoporosis, lasofoxifene 0.5mg daily reduced the risk of radiographic vertebral fractures after three years. At the end of […]